Loading stock data…
Conexeu Sciences Inc. (CNXU)
$10.24-0.72 (-6.57%)
After Hours$11.00+0.76 (+7.42%)· Last close Jun 29
Conexeu Sciences Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$1.72M↓ | -$332,721 |
| Net Income | -$1.72M↓ | -$290,064 |
Peer Comparison
JNJUNHPFE
Fundamentals
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$286.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.43%
Volume
Today's trading volume
42,299
Recent News
Is Conexeu Sciences (CNXU) Quietly Redefining Its Commercial Ambitions With CXU Platform Moves?
Conexeu Sciences recently expanded its leadership bench, adding three directors with deep healthcare and capital markets experience, appointing co-founder David Bogart as Chief Commercial Officer, and strengthening its advisory board as it advances the CXU™ regenerative tissue platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix program. At the same time, the company reported progress in scaling up manufacturing and regulatory preparations for its CXU wound care device, signaling a shift...
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Weiss Ratings analyst Chris Graebe outlines how Regulation A offerings let retail investors access private companies like FJET, NUCL, and CNXU before their public listings.
How Investors Are Reacting To Conexeu Sciences (CNXU) 3D-Printed Bioregenerative Breast Matrix Initiative
Conexeu Sciences Inc. recently initiated a preclinical development program at the Wake Forest Institute for Regenerative Medicine for B.R.E.A.S.T., a 3D-printed bioregenerative breast matrix built on its proprietary CXU extracellular matrix platform. The collaboration taps advanced tissue-organ bioprinting infrastructure to explore a resorbable, cell-guiding alternative to permanent breast implants, with potential to extend CXU technology across multiple medical and aesthetic markets. We...